---
title: "The tumor multi-omic landscape of endometrial cancers developed on a germline genetic background of adiposity"
description: |
  * **Objective**: This study used **Mendelian randomization (MR)** to investigate the causal effect of **germline genetic risk for adiposity (BMI)** on the **multi-omic landscape** (gene expression, somatic mutations, and immune microenvironment) of **endometrial cancers (EC)**.
  * **Key Findings**: Genetically predicted higher BMI was causally associated with increased expression of the oncogene **MDM2** in EC tumors. It was also linked to a detrimental change in the **tumor immune microenvironment**, specifically **decreasing CD4+ and cytotoxic T cell infiltration**.
  * **Conclusion**: The study suggests that germline adiposity fuels EC progression by promoting a more immunosuppressive tumor environment and activating key survival pathways, but not by altering the frequency of common somatic mutations.
date: last-modified
categories: [adiposity, endometrial cancer, germline genetics, mendelian randomization, multi-omics, somatic mutation, tcga, tumor microenvironment]
---

**PubMed:** [37873386](https://pubmed.ncbi.nlm.nih.gov/37873386/)
**DOI:** [10.1101/2023.10.09.23296765](https://doi.org/10.1101/2023.10.09.23296765)
**Overview generated by:** Gemini 2.5 Flash, 28/11/2025

## Key Findings: Linking Genetic Adiposity to Tumor Biology

This study used a **two-sample Mendelian randomization (MR)** approach to investigate how germline genetic variants associated with **higher Body Mass Index (BMI)/adiposity** causally influence the **multi-omic landscape** (gene expression, DNA methylation, somatic mutations, and tumor microenvironment) of subsequent **endometrial cancers (EC)**.

* **Causal Effect on Tumor Expression:** Genetically predicted higher BMI was causally associated with increased expression of the gene **MDM2** in EC tumors (FDR-corrected $P < 0.05$). MDM2 is a key regulator of the TP53 pathway and a potential oncogene, suggesting that the genetic effects of adiposity influence a critical tumor survival pathway.
* **Tumor Immune Microenvironment (TIME) Effect:** Higher genetically predicted BMI was also associated with significant changes in the **tumor immune microenvironment**. Specifically, it was causally linked to:
    * **Decreased CD4+ T cell infiltration** ($P < 0.05$ FDR-corrected).
    * **Decreased cytotoxic T cell infiltration** ($P < 0.05$ FDR-corrected).
    * This finding suggests that germline adiposity may drive EC progression by creating a more **immunosuppressive tumor microenvironment**, potentially reducing the efficacy of immunotherapies.
* **No Causal Effect on Somatic Mutations:** The study found **no strong evidence** that genetically predicted BMI causally influenced the frequency of common EC somatic mutations (e.g., in *PTEN*, *PIK3CA*, or *TP53*), indicating that the adiposity-driven mechanism likely impacts tumor biology through changes in gene expression and the TIME, rather than through altering fundamental mutation rates.

## Study Design and Methods

### Study Design

This was a **two-sample Mendelian randomization (MR) study** that integrated summary-level GWAS data for the exposure (adiposity) with tumor-specific multi-omic data from the outcome (EC tumor biology).

### Data Sources and Exposures

* **Exposure (Adiposity):** Genetic variants (SNPs) associated with **BMI** were used as instrumental variables (IVs). A total of 170 independent BMI-associated SNPs were selected from a large GWAS meta-analysis ($n=806,834$).
* **Outcome (EC Tumor Multi-omics):** Multi-omic data for **Endometrial Cancer (EC)** were sourced from **The Cancer Genome Atlas (TCGA)** and other large consortia:
    * **Transcriptomics:** Gene expression levels for 17,929 genes.
    * **Methylomics:** DNA methylation levels across 11,108 CpG sites.
    * **Somatic Mutations:** Frequency of common driver mutations.
    * **Tumor Microenvironment:** Estimated immune cell infiltration levels (e.g., cytotoxic T cells, CD4+ T cells) derived from gene expression profiles using validated methods (e.g., CIBERSORT).

### Statistical Analysis

1.  **Mendelian Randomization (MR):** The **Inverse-Variance Weighted (IVW) method** was used as the primary MR approach to estimate the causal effect of genetically predicted BMI on each multi-omic feature. The results were reported as the change in the outcome feature per 1 standard deviation (SD) increase in BMI.
2.  **Sensitivity Analyses:** Robust MR methods, including **MR-Egger**, were used to test for and account for potential horizontal pleiotropy.
3.  **Multiple Testing Correction:** All results were subjected to a stringent **False Discovery Rate (FDR) correction** (Benjamini-Hochberg) to account for the large number of molecular outcomes tested (over 29,000 multi-omic traits).

## Conclusions and Recommendations

The study concludes that a person's **germline genetic predisposition to adiposity** plays a significant, causal role in shaping the molecular and immunological characteristics of their subsequent endometrial tumors.

* **Mechanistic Insight:** The findings suggest that the metabolic/endocrine consequences of adiposity (driven by the germline genome) likely fuel tumor growth by activating oncogenic pathways (**MDM2** overexpression) and suppressing anti-tumor immunity (reduced **CD4+ and cytotoxic T cell infiltration**).
* **Clinical Implications:** This mechanistic understanding could inform targeted interventions. For instance, in individuals with high genetic adiposity risk, combining weight-loss interventions with treatments that counteract MDM2 activity or enhance T cell infiltration might prove particularly effective for EC prevention or therapy.
* **Future Work:** The authors recommend applying this multi-omic MR approach to investigate the causal influence of genetic adiposity on other obesity-related cancers (e.g., breast and colorectal cancer) and to explore the specific pathways driving the suppression of anti-tumor immunity.